Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight

globenewswire.com
WEX Wex Pharmaceuticals' Halneuron has received US FDA fast-track status for treating chemotherapy-induced neuropathic pain (CINP) and is in Phase IIb trials, indicating strong potential for market growth. ATX ASMF VELO Veloxis Pharmaceuticals is involved with ART-123, which is in a Phase III clinical trial in the US for CIPN, indicating positive development and market potential. WSNT LEX VRTX Vertex Pharmaceuticals is listed among companies in the peripheral neuropathic pain and diabetic peripheral neuropathy markets, but its direct involvement or progress in the CIPN market is not specified, resulting in neutral sentiment. PFE Pfizer is mentioned in relation to diabetic neuropathy companies, but its specific role or progress in the CIPN market is not detailed, leading to neutral sentiment. REGN Regeneron Pharmaceuticals is mentioned in relation to diabetic neuropathy companies, but its specific role or progress in the CIPN market is not detailed, leading to neutral sentiment. LLY GSK GlaxoSmithKline is mentioned in the context of peripheral neuropathic pain clinical trials, but its specific role or progress in the CIPN market is not detailed, leading to neutral sentiment. NVO Novo Nordisk is mentioned in relation to diabetic neuropathy companies, but its specific role or progress in the CIPN market is not detailed, leading to neutral sentiment. ISPC Ionis Pharmaceuticals is mentioned in relation to diabetic neuropathy companies, but its specific role or progress in the CIPN market is not detailed, leading to neutral sentiment. MRK Merck & Co. is mentioned in relation to peripheral neuropathic pain companies, but its specific role or progress in the CIPN market is not detailed, leading to neutral sentiment. SCIX

New York, USA, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight

The chemotherapy-induced peripheral neuropathy market is emerging as a high-value market opportunity driven by the lack of approved therapies and the significant unmet clinical need. Rising global chemotherapy usage, especially with neurotoxic agents, continues to expand the patient pool. Additionally, the launch of emerging therapies such as Halneuron (Wex Pharmaceuticals), ATX01 (AlgoTx), ART-123 (Asahi Kasei Pharma/Veloxis Pharmaceuticals), WST-057 (WinSanTor, Inc.), and others will further fuel the CIPN market growth.

DelveInsight’s Chemotherapy-induced Peripheral Neuropathy Market Insights report includes a comprehensive understanding of current treatment practices, emerging CIPN drugs, market share of individual therapies, and current and forecasted CIPN market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Chemotherapy-induced Peripheral Neuropathy Market Summary

Discover which CIPN medications are expected to grab the market share @ Chemotherapy-induced Peripheral Neuropathy Market Report

Key Factors Driving the Growth of the CIPN Market

Rising Cancer Incidence & Chemotherapy Usage

The increasing incidence of cancer worldwide, fueled by aging populations, changing lifestyles, and environmental factors, leads to greater use of chemotherapy treatments. As more patients survive cancer due to improved detection and therapy, prolonged and repeated chemotherapy raises the risk and awareness of CIPN.

Broader Adoption of Multimodal and Non-Pharmacological Therapies

Complementary approaches, such as acupuncture, transcutaneous electrical nerve stimulation (TENS), and other non-pharmacological interventions, are increasingly accepted as part of comprehensive care to relieve symptoms and improve quality of life.

Emergence of Novel CIPN Drugs

A few emerging therapies, such as Halneuron (Wex Pharmaceuticals), ATX01 (AlgoTx), ART-123 (Asahi Kasei Pharma/Veloxis Pharmaceuticals), WST-057 (WinSanTor, Inc.), and others, are in late-stage clinical development.

Chemotherapy-induced Peripheral Neuropathy Market Analysis

At present, no approved treatments exist specifically for CIPN. Management largely relies on off-label medications aimed at easing symptoms. Although numerous agents commonly used for neuropathic pain have been evaluated, none have shown clear effectiveness in preventing CIPN.

Patients experiencing CIPN symptoms are generally prescribed off-label drug classes such as alpha-2-delta ligands (anticonvulsants), serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), opioids, and topical analgesics, all of which are standard options for neuropathic pain relief.

Several late-stage investigational therapies, including HALNEURON (tetrodotoxin/TTX), ATX01, and ART-123, are progressing through advanced clinical trials. The introduction of these new treatments between 2025 and 2034 is expected to reshape the CIPN landscape across the 7MM, potentially driving a shift toward disease-modifying therapeutic strategies and boosting market growth.

Learn more about the CIPN treatment options @ Chemotherapy-induced Peripheral Neuropathy Treatment Market

Chemotherapy-induced Peripheral Neuropathy Competitive Landscape

Some of the CIPN drugs in clinical trials include Halneuron (Wex Pharmaceuticals), ATX01 (AlgoTx), ART-123 (Asahi Kasei Pharma/Veloxis Pharmaceuticals), WST-057 (WinSanTor, Inc.), and others.

Wex Pharmaceuticals’ Halneuron (tetrodotoxin, TTX) is a small-molecule therapy aimed at treating moderate to severe neuropathic pain without the typical side effects of opioids. TTX works by blocking voltage-gated sodium channels (VGSCs) on pain-conducting nerves, which play a key role in chronic pain. The US FDA has granted Halneuron fast-track status for treating chemotherapy-induced neuropathic pain (CINP). It is currently in a Phase IIb trial enrolling patients with CIPN resulting from platinum- or taxane-based chemotherapy.

AlgoTx’s ATX01 is a first-in-class topical treatment for peripheral neuropathic pain, with a primary focus on CIPN. The formulation is designed to act locally within the epidermis and dermis, where nerve fiber damage occurs, thereby reducing systemic exposure and minimizing side effects. AlgoTx recently completed the ACT Phase II study in the US and Europe, assessing ATX01 in patients with CIPN.

Asahi Kasei Pharma/Veloxis Pharmaceuticals’ ART-123 is a recombinant human soluble thrombomodulin containing the extracellular region of thrombomodulin. It exerts anticoagulant activity by enhancing protein C activation and also displays anti-inflammatory and anti-fibrinolytic effects through activation of TAFI. Additional anti-inflammatory actions have been reported through direct binding to HMGB1 and promoting its thrombin-mediated degradation. ART-123 is currently in a Phase III clinical trial in the US for treating CIPN.

The anticipated launch of these emerging CIPN therapies are poised to transform the CIPN market landscape in the coming years. As these cutting-edge CIPN therapies continue to mature and gain regulatory approval, they are expected to reshape the CIPN market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about new treatment for CIPN, visit @ Chemotherapy-induced Peripheral Neuropathy Medication

Recent Developments in the CIPN Market

What is Chemotherapy-induced Peripheral Neuropathy?

Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-related side effect of several anticancer therapies—such as platinum compounds, taxanes, epothilones, vinca alkaloids, and newer drugs like bortezomib. It often forces clinicians to lower doses or stop treatment altogether, and significantly diminishes the quality of life for cancer survivors.

Chemotherapy-induced Peripheral Neuropathy Epidemiology Segmentation

The CIPN epidemiology section provides insights into the historical and current CIPN patient pool and forecasted trends for the leading markets. In 2024, the highest number of CIPN cases in the United States was observed in moderate CIPN with ~360K cases, followed by mild and severe cases.

The CIPN market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets segmented into:

Download the report to understand CIPN management @ Chemotherapy-induced Peripheral Neuropathy Treatment Options

Scope of the Chemotherapy-induced Peripheral Neuropathy Market Report

Discover more about CIPN drugs in development @ Chemotherapy-induced Peripheral Neuropathy Clinical Trials

Table of Contents

Related Reports

Chemotherapy-induced Peripheral Neuropathy Clinical Trial Analysis

Chemotherapy-induced Peripheral Neuropathy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CIPN companies, including Grünenthal GmbH, AlgoTherapeutix, Wex Pharmaceuticals Inc., among others.

Peripheral Neuropathic Pain Market

Peripheral Neuropathic Pain Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key peripheral neuropathic pain companies, including Lexicon Pharmaceuticals, Merz Therapeutics, Apurano Pharmaceuticals, Vertex Pharmaceuticals, WEX Pharmaceuticals, Scilex Holding Company, among others.

Peripheral Neuropathic Pain Clinical Trials Analysis

Peripheral Neuropathic Pain Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Peripheral Neuropathic Pain companies, including Haisco Pharmaceutical Group, GlaxoSmithKline, Algiax Pharmaceuticals, Apurano Pharmaceuticals GmbH, Eli Lilly and Company, Shanghai SIMR Biotechnology, Lexicon Pharmaceuticals, among others.

Diabetic Peripheral Neuropathy Market

Diabetic Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetic peripheral neuropathy companies including Grünenthal, Averitas Pharma, Daiichi Sankyo, Helixmith, Vertex Pharmaceuticals, among others.

Diabetic Neuropathy Market

Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetic neuropathy companies, including Novo Nordisk, Ionis Pharmaceuticals, Pfizer, Regeneron, NeuroMetrix, among others.

DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Pharmaceutical Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn| Facebook| Twitter